Search results for "Stable angina"

showing 9 items of 89 documents

A Dose-Dependent Improvement in Exercise Tolerance in Patients With Stable Angina Treated With Mildronate: A Clinical Trial “MILSS I”

2011

Objective. To assess the efficacy of various doses of Mildronate in combination with standard therapy for the exercise tolerance of patients with stable angina pectoris. The primary efficacy variable was the change in exercise time in bicycle ergometry from the baseline to 12 weeks of treatment. The secondary endpoints were the changes in maximum achieved load and time to the onset of angina from the baseline to week 12. Material and Methods. A total of 512 patients with chronic coronary heart disease who had ischemia as the limiting factor in the exercise test from 72 study centers in 4 countries were enrolled in this prospective, randomized, double-blind, placebo controlled phase 2 study.…

medicine.medical_specialtybusiness.industryIschemiaPhases of clinical researchGeneral Medicinemedicine.diseasePlaceboEffective dose (pharmacology)law.inventionSurgeryAnginaClinical trialDose–response relationshipmildronate; partial fatty acid oxidation inhibition; exercise tolerance; stable anginaRandomized controlled triallawAnesthesiamedicinebusinessMedicina; Volume 47; Issue 10; Pages: 78
researchProduct

Aktuelle Komplikationsrate der perkutanen transluminalen Koronarangioplastie bei stabiler und unstabiler Angina

2008

During a four-year period (1983-1986) percutaneous transluminal coronary angioplasty (PTCA) was performed on 930 patients with stable or unstable angina with a mortality rate of 0.4%. A transmural myocardial infarct developed in 1.1% and 1.0% of patients required an urgent aorto-coronary bypass. Thus the total rate of severe cardiac complications was 2.5%. Compared with the years 1983-1985, there was in 1986 a significant fall in the number of deaths and of myocardial infarcts from 2.2% to 0.5% (P less than 0.05), while there was a nonsignificant increase in emergency coronary bypass surgery from 0.7 to 1.3%. Patients with unstable angina compared with those with stable angina had a signifi…

medicine.medical_specialtybusiness.industryUnstable anginaIncidence (epidemiology)Mortality ratemedicine.medical_treatmentInfarctionGeneral Medicinemedicine.diseaseAnginaBypass surgeryInternal medicineAngioplastyCardiologyMedicinecardiovascular diseasesMyocardial infarctionbusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

Antithrombotic therapy in acute coronary syndromes

2000

Current therapy of acute coronary syndromes (i.e., unstable angina and non-Q-wave myocardial infarction, Q-wave myocardial infarction) consists of thrombolytic, anti-platelet, and anti-coagulant therapy. In most cases of acute coronary syndromes, the pathogenesis is a mural thrombus formation on a ruptured or eroded atherosclerotic plaque. Both platelets and thrombin play an essential role in the pathophysiology of acute coronary syndromes. Aspirin and heparin are essential treatments for patients with acute coronary syndromes. Novel thrombin and platelet inhibitors have been developed and demonstrated useful effects for improving both acute and long-term clinical outcomes in acute coronary…

medicine.medical_specialtybusiness.industryUnstable anginaReteplaseTirofibanHeparinClopidogrelmedicine.diseaseInternal medicinemedicineAbciximabEptifibatideCardiologyMyocardial infarctionbusinessmedicine.drug
researchProduct

Interventional cardiology: Differences in the morphology of unstable and stable coronary lesions and their impact on the mechanisms of angioplasty. A…

1996

The aim of this study was to compare the morphology of stable and unstable coronary lesions using intravascular ultrasound in patients undergoing coronary balloon angioplasty and to determine whether lesion morphology had any influence on the mechanism of balloon angioplasty. Thirty three (15 stable and 18 unstable) patients undergoing single lesion percutaneous transluminal coronary angioplasty were studied with intravascular ultrasound before and after intervention. All examinations, recorded on S-VHS video tape, were studied off-line and matched sites from the point of minimum lumen area after the procedure and the corresponding site prior to intervention were compared. The morphology of…

medicine.medical_specialtymedicine.diagnostic_testInterventional cardiologybusiness.industryUnstable anginamedicine.medical_treatmentLumen (anatomy)medicine.diseaseAnginaLesionInternal medicineAngioplastyIntravascular ultrasoundmedicineCardiologyThrombusmedicine.symptomCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

An FFR CT diagnostic strategy versus usual care in patients with suspected coronary artery disease planned for invasive coronary angiography at Germa…

2017

Aim Diagnostic evaluation practices for suspected coronary artery disease (CAD) may vary between countries. Our objective was to compare a CT-derived fractional flow reserve (FFRCT) diagnostic strategy with usual care in patients with planned invasive coronary angiography (ICA) enrolled in the PLATFORM (Prospective Longitudinal Trial of FFRCT: Outcome and Resource Impacts) study at German sites. Methods Patients were divided into two consecutive observational cohorts, receiving either usual care or CT angiography (CTA)/FFRCT. The primary endpoint was the percentage of patients planned for ICA, with no obstructive CAD on ICA within 90 days. Secondary endpoints included death, myocardial infa…

medicine.medical_specialtymedicine.diagnostic_testUnstable anginabusiness.industrySubgroup analysisFractional flow reserve030204 cardiovascular system & hematologymedicine.diseaseSurgeryCoronary artery disease03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineAngiographymedicineClinical endpoint030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular MedicinebusinessOpen Heart
researchProduct

Effects of Ciprostene on Restenosis Rate during Therapeutic Transluminal Coronary Angioplasty

1992

Ciprostene, a chemically stable prostacyclin analog was studied for its effects on restenosis in patients with coronary artery disease undergoing therapeutic percutaneous transluminal coronary angioplasty (PTCA). In a double-blind, randomized trial 32 patients were randomized to receive either ciprostene or the respective placebo. The infusion started intracoronarily at a rate of 40 ng/kg/min 20 min before introduction of the balloon catheter into the coronary artery. Thereafter infusion was continued intravenously for 36 hours at a rate of 120 ng/kg/min and a tapering off period until 48 hours. The quantitative analyses of the degree of coronary artery stenoses on the angiographic films be…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industryUnstable anginamedicine.medical_treatmentBalloon catheterHemodynamicsmedicine.diseaseCoronary artery diseasemedicine.anatomical_structureRestenosisAngioplastyInternal medicineAngiographyCardiologyMedicinecardiovascular diseasesbusinessArtery
researchProduct

Percutaneous Recanalization of Chronic Total Occlusions : 2019 Consensus Document from the EuroCTO Club

2019

Since its inception in December 2006, the EuroCTO Club has strived to provide the framework for state-of-the-art chronic total occlusion (CTO) percutaneous coronary intervention (PCI) in Europe and nearby regions. Among its initiatives, the EuroCTO Club has published a set of recommendations regarding the technical aspects of CTO PCI, whose last edition dates to 2012. The EuroCTO Club consensus document discusses CTO PCI clinical indications, techniques and equipment use, as well as the qualifications of operators/centres. Given the considerable amount of progress made by this subspecialty in recent years, there is a need for an updated document that includes data from recent clinical trial…

stable anginaPercutaneousConsensusmedicine.medical_treatmentMEDLINE030204 cardiovascular system & hematologySubspecialtyCoronary AngiographyTotal occlusion03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionPercutaneous Coronary Intervention.drug-eluting stentMedicineHumans030212 general & internal medicineRegistrieschronic total occlusionbusiness.industryPercutaneous coronary interventionmedicine.diseaseClinical trialEuropeTreatment OutcomeCoronary OcclusionConventional PCIChronic DiseaseClubMedical emergencyCardiology and Cardiovascular Medicinebusiness
researchProduct

Radiation Exposure for Percutaneous Interventions of Chronic Total Coronary Occlusions in a Multicenter Registry: The Influence of Operator Variabili…

2021

Aims. Radiation exposure is a limiting factor for percutaneous coronary interventions (PCI) of chronic total coronary occlusion (CTO) lesions. This study was designed to analyze changes in patient radiation dose for CTO-PCI and parameters associated with radiation dose. Methods and Results. We analyzed a cohort of 12,136 procedures performed by 23 operators between 2012 and 2017 from the European Registry of CTO-PCI. Radiation exposure was recorded as air kerma (AK) and dose area product (DAP). A dose rate index (DRI) was calculated as AK per fluoroscopy time to normalize for individual differences in fluoroscopy time. The lesion complexity increased from Japanese-CTO (J-CTO) score of 2.19 …

stable anginapercutaneous coronary interventionchronic coronary total occlusionRadiation ExposureCoronary AngiographyTreatment OutcomeCoronary OcclusionRisk FactorsFluoroscopyChronic DiseaseHumansRegistriesradiation protection
researchProduct

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2020

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

unstable anginaMyocardial ischaemia[SDV]Life Sciences [q-bio]Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]dual antithrombotic therapyGuidelineheparin030204 cardiovascular system & hematologyPlatelet inhibitionantiplatelet0302 clinical medicineST segmentMedicinedabigatranMyocardial infarctionguidelinesglycoprotein iib/iiia inhibitorsanticoagulationNon-ST Elevated Myocardial InfarctionrivaroxabanComputingMilieux_MISCELLANEOUSreproductive and urinary physiologydiabetesbleedingsbivalirudinatherothrombosiDisease ManagementangioplastyGuidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet • apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/ IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction • nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations • revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable anginaenoxaparinGeneral MedicineClopidogrel3. Good healthearly invasive strategymyocardial infarctiontriple therapy030220 oncology & carcinogenesisHigh sensitivity troponinembryonic structuresCardiologyPlatelet aggregation inhibitorrevascularizationbiological phenomena cell phenomena and immunityCardiology and Cardiovascular MedicineTicagrelormedicine.drugHumanrecommendationAcute coronary syndromemedicine.medical_specialtyaspiringlycoprotein IIb/IIIa inhibitornon-ST-elevation myocardial infarctionapixabanrhythm monitoringEuropean Society of Cardiologyticagrelor03 medical and health sciencesnitrateatherothrombosisbetablockersInternal medicineacute cardiac careminocachest pain unitDiseases of the circulatory (Cardiovascular) systemHumansIn patientAcute Coronary SyndromeclopidogrelUnstable anginaurogenital systemnitratesbusiness.industryfondaparinuxbetablockerArrhythmias Cardiac030229 sport sciencesbleedingmedicine.diseasemyocardial ischaemiaplatelet inhibitionprasugreldiabeteGlycoprotein IIb/IIIa inhibitorsRC666-701bypass surgerySettore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARErecommendationsedoxabanhigh-sensitivity troponinstentbusinessPlatelet Aggregation Inhibitorscangrelor
researchProduct